FDA Approves Igalmi for Agitation | Psychiatric News
Apr 25, 2022 · The Food and Drug Administration (FDA) in April approved a sublingual formulation of dexmedetomidine under the brand name of Igalmi for the treatment of agitation …
Warnings of new deadly chemical in street drug supply : NPR
May 29, 2024 · Public health officials say Mexican cartels and drug gangs inside the U.S. are mixing a dangerous chemical sedative called medetomidine into fentanyl and other drugs sold …
UNC School of Medicine, BioXcel Therapeutics Team Up to Tackle …
Oct 15, 2024 · U.S. Department of Defense awarded $2.8 million to UNC Institute for Trauma Recovery researchers led by Samuel McLean, MD, to test the safety and efficacy of BXCL501 …
Use of dexmedetomidine in critical-ill patients: is it time to look …
Aug 29, 2023 · Dexmedetomidine is an alpha-2 (ɑ2) adrenergic receptor and imidazoline type 2 receptor agonist that received Food and Drug Administration (FDA) approval in 1999 as a …
Study finds use of sedative dexmedetomidine decreases cerebral ...
Nov 4, 2024 · The study assessed the effect of the sedative dexmedetomidine (Dex) on patients undergoing CAS. It found that only 11% of patients receiving Dex developed cerebral …
Dexmedetomidine or Propofol for Sedation in Mechanically …
Feb 2, 2021 · Guidelines currently recommend targeting light sedation with dexmedetomidine or propofol for adults receiving mechanical ventilation. Differences exist between these sedatives …
BioXcel Therapeutics Announces U.S. Department of Defense …
Oct 15, 2024 · Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI™ (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally …
Efficacy and safety of dexmedetomidine for analgesia and
Oct 16, 2023 · Dexmedetomidine, a highly selective alpha-2-adrenoreceptor agonist, has piqued interest as a viable alternative for neonates, owing to its potential analgesic and …
Dexmedetomidine: present and future directions - PMC
Dexmedetomidine is a potent, highly selective α-2 adrenoceptor agonist, with sedative, analgesic, anxiolytic, sympatholytic, and opioid-sparing properties. Dexmedetomidine induces a unique …
Dexmedetomidine Transdermal Patch Fast Tracked for Postop …
Jun 21, 2023 · Teikoku Pharma granted FDA Fast Track designation for TPU-006, a novel 4-day dexmedetomidine transdermal system for postoperative pain management. News release. …
- Some results have been removed